Related Experiment Video

Updated: May 14, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer

Kunihiko Kobayashi1, Koichi Hagiwara

  • 1Saitama Medical University, Moroyama, Japan. kobakuni@saitama-med.ac.jp

Targeted Oncology
|January 31, 2013
PubMed

Insights

For advanced non-small cell lung cancer with EGFR mutations, tyrosine kinase inhibitors (TKIs) significantly improve progression-free survival compared to chemotherapy. TKIs are now the standard first-line therapy, enhancing quality of life.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Non-small cell lung cancer (NSCLC) treatment historically relied on cytotoxic chemotherapy with limited efficacy.
  • Discovery of epidermal growth factor receptor (EGFR) gene mutations in a subset of NSCLC revealed sensitivity to EGFR tyrosine kinase inhibitors (TKIs).

Purpose of the Study:

  • To evaluate the efficacy of EGFR TKIs compared to standard chemotherapy as first-line treatment for advanced EGFR-mutated NSCLC.
  • To determine the impact of TKIs on progression-free survival (PFS), overall survival (OS), and quality of life (QoL).

Main Methods:

  • Four prospective phase III studies (NEJ 002, WJTOG 3405, OPTIMAL, EUROTAC) compared EGFR TKIs (gefitinib or erlotinib) with cytotoxic chemotherapy.
  • Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS) and quality of life (QoL).

Main Results:

  • TKIs demonstrated significantly longer PFS compared to chemotherapy (hazard ratio [HR] = 0.16-0.49).
  • While OS was similar in one study (HR = 0.89), gefitinib treatment maintained a better quality of life.
  • These findings were consistent across multiple studies conducted from 2009 to 2011.

Conclusions:

  • EGFR tyrosine kinase inhibitors (TKIs) should be considered the standard first-line therapy for advanced NSCLC patients with EGFR mutations.
  • The introduction of TKIs represents a significant advancement in the treatment algorithm for advanced NSCLC.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...